MCM6 indicates adverse tumor features and poor outcomes and promotes G1/S cell cycle progression in neuroblastoma.

Yaoyao GuXiaoxiao HuXiaowei LiuCheng ChengKai ChenYeming WuZhixiang Wu

Published in: BMC cancer (2021)

MCM6 is considered to be the driving force of G1/S cell cycle progression, and it is also a prognostic marker and a potential novel therapeutic target in neuroblastoma.

Keyphrases

cell cycle
cell proliferation
single molecule
emergency department
type diabetes
human health
adipose tissue
adverse drug
electronic health record